The future of the global pertussis vaccine market looks promising with opportunities in the vaccination center, hospital, and clinic markets. The global pertussis vaccine market is expected to reach an estimated $9.1 billion by 2030 with a CAGR of 5.6% from 2024 to 2030. The major drivers for this market are growing awareness of the importance of pertussis vaccination, supportive government initiatives to promote pertussis vaccination, and continuous development of new pertussis vaccines.
Some of the key questions
answered in this exclusive report are:
Q.1. What are some of
the most promising, high-growth opportunities for the pertussis vaccine market
by type (Dtap vaccine and Tdap vaccine), end use (vaccination centers,
hospitals, clinics, and others), and region (North America, Europe, Asia
Pacific, and the Rest of the World)?
Q.2. Which segments will
grow at a faster pace and why?
Q.3. Which region will
grow at a faster pace and why?
Q.4. What are the key
factors affecting market dynamics? What are the key challenges and business
risks in this market?
Q.5. What are the
business risks and competitive threats in this market?
Q.6. What are the
emerging trends in this market and the reasons behind them?
Q.7. What are some of
the changing demands of customers in the market?
Q.8. What are the new
developments in the market? Which companies are leading these developments?
Q.9. Who are the major
players in this market? What strategic initiatives are key players pursuing for
business growth?
Q.10. What are some of
the competing products in this market and how big of a threat do they pose for
loss of market share by material or product substitution?
Q.11. What M&A
activity has occurred in the last 5 years and what has its impact been on the
industry?
Market Segmentation:
In this market, Dtap
vaccine and Tdap vaccine are the major segments of pertussis vaccine market by
type. Lucintel forecasts that Dtap will remain the larger segment due to its
significant use as combinated vaccine that protects against diphtheria,
tetanus, and pertussis.
Within this market,
vaccination center will remain the largest segment as its convenient and
accessible as well as offer a wide range of vaccines, including pertussis
vaccines.
North America is
expected to witness highest growth over the forecast period due to increasing
number of geriatric population and rising pertussis death cases in the region.
Protein Sciences,
Glaxosmithkline, Sanofi Pasteur, Seqirus, Merck Sharp & Dohme, Novartis,
and Astellas Pharma are the major suppliers in the pertussis vaccine market.
About
Lucintel
Lucintel, the premier global
management consulting and market research firm, creates winning strategies for
growth. It offers market assessments, competitive analysis, opportunity
analysis, growth
consulting, M&A, and due diligence services to executives and
key decision-makers in a variety of industries.
Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. 972.636.5056
Related Reports
1. Pharmaceutical Contract Manufacturing Market
3. Stent Market
5. 3D
Printing Medical Device Market
8. Medical Lifting Sling
Market
10. Stretcher Market
No comments:
Post a Comment